Assessing the long-term economic impact of wheezing episodes after severe RSV disease in children from Argentina: a cost of illness analysis
IntroductionThere is lack of available data on the economic burden of wheezing episodes after severe respiratory syncytial virus (RSV) infection. This study aimed to assess the cost incurred for wheezing episodes after a severe RSV infection in children from Argentina, considering both the public he...
Uloženo v:
| Vydáno v: | BMJ public health Ročník 2; číslo 1; s. e000975 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
England
BMJ Publishing Group Ltd
30.07.2024
BMJ Publishing Group |
| Témata: | |
| ISSN: | 2753-4294, 2753-4294 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Shrnutí: | IntroductionThere is lack of available data on the economic burden of wheezing episodes after severe respiratory syncytial virus (RSV) infection. This study aimed to assess the cost incurred for wheezing episodes after a severe RSV infection in children from Argentina, considering both the public health system and societal perspectives.MethodsA prospective cohort was conducted from 2014 to 2022 to assess the cost of illness of wheezing episodes after severe RSV disease in children from Buenos Aires, Argentina. Direct medical and non-medical costs were estimated, along with indirect costs per episode and patient. Data pertaining to healthcare resource utilisation, indirect expenses and parental out-of-pocket costs were obtained. The overall cost per hospitalisation and health visits was calculated. Costs were quantified in US dollars using the average exchange rate on the specific date of data collection.ResultsA total of 256 infants experienced severe RSV disease during their first year of life and were followed over a 5-year period in Buenos Aires. Overall, 150 children between 12 and 60 months presented 429 wheezing episodes. The median number of wheezing episodes per patient was 5 (IQR 3–7). The mean cost per wheezing episode was US$191.01 (95% CI 166.37 to 215.64). The total cost per episode of wheezing was significantly higher (p<0.001) in infants under 12 months of age (207.43, 95% CI 154.3 to 260.6) compared with older toddler. The average cumulative cost associated to wheezing per patient was US$415.99 (95% CI 313.35 to 518.63). Considering both acute RSV disease and long-term wheezing outcomes, the cumulative mean cost per patient was US$959.56 (95% CI 832.01 to 1087.10).ConclusionsThis study reveals the economic impact of prolonged wheezing resulting from severe acute RSV infection on Argentina’s public health system and society. The estimates obtained serve as valuable inputs for informing cost-effectiveness analyses of upcoming RSV preventive interventions. |
|---|---|
| Bibliografie: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Additional supplemental material is published online only. To view, please visit the journal online (https://doi.org/10.1136/bmjph-2024-000975). RL and MTC contributed equally. FPP reports grants and personal fees from Janssen, Pfizer, Sanofi and Merck, outside the submitted work. RL reports grants and/or personal fees from Merck, Pfizer and Janssen, outside the submitted work. EV was employed at PATH during her collaborations on this study; she is currently an employee of Pfizer. Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise. |
| ISSN: | 2753-4294 2753-4294 |
| DOI: | 10.1136/bmjph-2024-000975 |